产后即刻血糖值与妊娠期糖尿病患者持续性胰岛素抵抗的相关性
本研究为回顾性队列研究,纳入2009至2019年两家郊区医院分娩的367例妊娠期糖尿病患者,评估产后第1天空腹血糖与产后4至12周口服葡萄糖耐量试验诊断的持续性胰岛素抵抗的关联。多因素分析显示,与产后第1天空腹血糖<95 mg/dL相比,血糖95至109 mg/dL(aOR 1.10,95%CI 0.58-2.07,P=.77)和≥110 mg/dL(aOR 1.01,95%CI 0.44-2.30,P=.99)与产后异常口服葡萄糖耐量试验结果均无显著关联。结论认为产后第1天空腹血糖与产后4至12周持续性胰岛素抵抗无关。
要点
- 产后第1天空腹血糖≥95至109 mg/dL与<95 mg/dL相比,产后异常OGTT风险无显著差异(aOR 1.10,95%CI 0.58-2.07)。
- 产后第1天空腹血糖≥110 mg/dL与<95 mg/dL相比,产后异常OGTT风险无显著差异(aOR 1.01,95%CI 0.44-2.30)。
- 产后第1天空腹血糖95 mg/dL识别产后空腹血糖受损、糖耐量受损或2型糖尿病的敏感性为20.1%(95%CI 13.8-27.8%),特异性为81.2%(95%CI 76.4-85.4%)。
核心结论
- 产后第1天空腹血糖与产后4至12周持续性胰岛素抵抗无显著关联。
研究设计与样本
- 回顾性队列研究,纳入2009至2019年在2家郊区医院分娩的367例妊娠期糖尿病单胎妊娠患者,要求有产后第1天空腹血糖和产后4至12周口服葡萄糖耐量试验完整数据。
主要发现
- 产后第1天空腹血糖<95 mg/dL者占69.5%(255/367),95至109 mg/dL者占19.9%(73/367),≥110 mg/dL者占10.6%(39/367)。
- 多因素分析中,与产后第1天空腹血糖<95 mg/dL相比,95至109 mg/dL组产后异常口服葡萄糖耐量试验的aOR为1.10(95%CI 0.58-2.07,P=.77),≥110 mg/dL组aOR为1.01(95%CI 0.44-2.30,P=.99)。
- 产后第1天空腹血糖95 mg/dL识别产后空腹血糖受损、糖耐量受损或2型糖尿病的敏感性为20.1%(95%CI 13.8-27.8%),特异性为81.2%(95%CI 76.4-85.4%),阳性预测值为32.2%(95%CI 22.6-43.1%),阴性预测值为69.7%(95%CI 64.7-74.3%)。
- 产后第1天空腹血糖95 mg/dL识别产后4至12周2型糖尿病的敏感性为1.79%(95%CI 0.2-6.3%),特异性为98.4%(95%CI 96.0-99.6%),阳性预测值为33.3%(95%CI 4.3-77.7%),阴性预测值为69.6%(95%CI 64.6-74.3%)。
关键数值与推荐
- 妊娠期糖尿病诊断标准为50克1小时口服葡萄糖耐量试验值≥200 mg/dL,或3小时葡萄糖耐量试验中≥2项值超过既定阈值(Carpenter-Coustan标准)。
- 产后空腹血糖受损定义为空腹血糖≥100 mg/dL,糖耐量受损定义为产后葡萄糖耐量试验2小时血糖≥140 mg/dL。
- 产后第1天空腹血糖分为3类:<95、≥95至109、≥110 mg/dL进行分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gestational diabetes (GDM) affects approximately 6% of pregnancies and has critical maternal and neonatal implications.1 About 20-33% of these patients have insulin resistance or type 2 diabetes when evaluated at 6 to 12 weeks postpartum, however only approximately half of the affected patients return for postpartum testing.2-5 Fasting glucose during delivery hospitalization is correlated with fasting glucose on oral glucose tolerance testing (OGTT) at 4 to 12 weeks postpartum, but there is limited data on the utility of this value to identify the patients at an increased risk for postpartum insulin resistance.3 We aimed to evaluate if higher fasting glucose values on postpartum day 1 (PPD1) are correlated with an increased risk of persistent insulin resistance at 4 to 12 weeks postpartum diagnosed on OGTT. STUDY DESIGN: We conducted a retrospective cohort study of patients with GDM who delivered from 2009 to 2019 at 2 suburban hospitals. Eligible patients had a singleton pregnancy affected by GDM with complete data on PPD1 fasting glucose and OGTT at 4 to 12 weeks postpartum. GDM was diagnosed by a 50 gram, 1-hour OGTT value of ≥200 mg/dL or a 3-hour glucose tolerance test with ≥2 values exceeding defined thresholds (Carpenter-Coustan criteria). Postpartum impaired fasting glucose was defined as a fasting glucose ≥100 mg/dL, and impaired glucose tolerance was defined as a 2-hour glucose ≥140 mg/dL on postpartum glucose tolerance testing. PPD1 fasting glucose values were divided into 3 categories (<95, ≥95 to 109, and ≥110 mg/dL) for analyses. Univariate analyses were performed using chi-squared, analysis of variance, and Wilcoxon rank-sum tests as appropriate to evaluate the association between an abnormal postpartum OGTT and demographic variables, clinical characteristics, and PPD1 glucose by glucose category. Logistic regression models were performed to adjust for variables that were determined a priori and those found to be significant (P<.05) in univariate analyses. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated using descriptive statistics. RESULTS: Our analysis included 367 patients (Figure), of which 69.5% (255/367) had a PPD1 glucose <95 mg/dL, 19.9% (73/367) had a PPD1 glucose of 95 to 109 mg/dL, and 10.6% (39/367) had a PPD1 glucose ≥110 mg/dL. In multivariate analysis, compared with PPD1 <95 mg/dL, there was no significant association between postpartum glucose categories and abnormal postpartum OGTT results (PPD1 glucose ≥95 to 109 mg/dL: aOR [adjusted odds ratio], 1.10; 95% CI [confidence interval], 0.58-2.07; P=.77; PPD1 glucose ≥110 mg/dL: aOR, 1.01; 95% CI, 0.44-2.30; P=.99, Table). Fasting glucose on PPD1 of 95 mg/dL had a sensitivity of 20.1% (95% CI, 13.8-27.8%), specificity of 81.2% (95% CI, 76.4-85.4%), positive predictive value of 32.2% (95% CI, 22.6-43.1%), and negative predictive value of 69.7% (95% CI, 64.7-74.3%) to identify patients with impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes postpartum. In identifying patients with type 2 diabetes at 4 to 12 weeks postpartum, fasting glucose of 95 mg/dL on PPD1 had a sensitivity of 1.79% (95% CI, 0.2-6.3%), specificity of 98.4% (95% CI, 96.0-99.6%), positive predictive value 33.3% (95% CI, 4.3-77.7%), and negative predictive value of 69.6% (95% CI, 64.6-74.3%). CONCLUSION: Fasting glucose on PPD1 was not associated with persistent insulin resistance at 4 to 12 weeks postpartum.
引用
- Eastman LM, de Los Reyes S, Dude A, et al. The association of immediate postpartum glucose values with persistent insulin resistance in patients with gestational diabetes. Am J Obstet Gynecol MFM. 2021. PMID: 34763121. doi:10.1016/j.ajogmf.2021.100526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。